Abstract:Abstract Parkinson’s disease (PD) is a chronic neurodegenerative disorder that affects the motor system. Increasing evidence indicates that lysosomal dysfunction is pivotal in the pathogenesis of PD, typically characterized by dysregulation of sphingolipids in lysosomes. ATP-binding cassette subfamily A member 5 (ABCA5) is a lysosomal transporter that mediates the removal of excess sphingomyelin from lysosomes. We therefore investigated whether the expression levels of ABCA5 are associated with sphingomyelin levels and α-synuclein pathology in PD. Firstly, we undertook a comprehensive assessment of the six sphingolipid classes that are part of the lysosomal salvage pathway in the disease-affected amygdala and disease-unaffected visual cortex using liquid chromatography-mass spectrometry. We found that sphingomyelin levels were significantly increased in PD compared to controls and correlated with disease duration only in the amygdala, whereas, the five other sphingolipid classes were slightly altered or unaltered. Concomitantly, the expression of ABCA5 was upregulated in the PD amygdala compared to controls and correlated strongly with sphingomyelin levels. Using neuronal cells, we further verified that the expression of ABCA5 was dependent on cellular levels of sphingomyelin. Interestingly, sphingomyelin levels were strongly associated with α-synuclein in the amygdala and were related to α-synuclein expression. Finally, we revealed that sphingomyelin levels were also increased in PD plasma compared to controls, and that five identical sphingomyelin species were increased in both the brain and the plasma. When put together, these results suggest that in regions accumulating α-synuclein in PD, ABCA5 is upregulated to reduce lysosomal sphingomyelin levels potentially as a protective measure. This process may provide new targets for therapeutic intervention and biomarker development for PD.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the protective effect of ATP - binding cassette sub - family A member 5 (ABCA5) on the elevation of sphingomyelin levels in Parkinson's disease (PD). Specifically, the study aims to evaluate whether the expression level of ABCA5 is related to sphingomyelin levels and α - synuclein pathology in PD and to explore the inter - relationships among these factors. By analyzing the changes in sphingomyelin and other sphingolipids in disease - affected regions (such as the amygdala) and unaffected regions (such as the visual cortex), the researchers hope to reveal the potential protective mechanism of ABCA5 in PD, which may provide new targets for treatment intervention and biomarker development in PD. ### Research Background Parkinson's disease is a chronic neurodegenerative disease that mainly affects the motor system. Increasing evidence shows that lysosomal dysfunction plays a crucial role in the pathogenesis of PD, especially the dysregulation of sphingolipids in lysosomes. ABCA5 is a lysosomal transporter responsible for removing excess sphingomyelin from lysosomes. Therefore, the researchers explored whether the expression level of ABCA5 is related to sphingomyelin levels and α - synuclein pathology in PD. ### Main Findings 1. **Increased Sphingomyelin Levels**: In the amygdala of PD patients, sphingomyelin levels were significantly increased and positively correlated with the duration of the disease course. The changes in the other five sphingolipids were small or non - existent. 2. **Up - regulated ABCA5 Expression**: In the amygdala of PD patients, the expression level of ABCA5 was significantly up - regulated and highly correlated with sphingomyelin levels. Cell experiments further confirmed that the expression of ABCA5 depends on intracellular sphingomyelin levels. 3. **Relationship between α - Synuclein and Sphingomyelin**: The expression of α - synuclein was strongly correlated with sphingomyelin levels in the amygdala of PD patients. Cell experiments showed that exogenous sphingomyelin treatment can increase the expression of α - synuclein, while inhibiting sphingomyelin synthesis reduces the expression of α - synuclein. 4. **Transcriptional Regulation of ABCA5**: The transcription of ABCA5 is regulated by peroxisome proliferator - activated receptor γ (PPARγ), which provides a potential drug - intervention pathway for controlling intracellular sphingomyelin levels. 5. **Sphingomyelin Levels in Blood**: The sphingomyelin levels in the plasma of PD patients were also significantly increased, and some sphingomyelin species were consistent with the changes in brain tissue, suggesting that they may serve as peripheral biomarkers for PD. ### Conclusion The research results indicate that ABCA5 may play a protective role in PD by reducing excessive sphingomyelin levels in lysosomes. This finding not only helps to understand the mechanism of sphingomyelin metabolism disorder in PD but also provides a new direction for treatment intervention and biomarker development in PD.

A protective role of ABCA5 in response to elevated sphingomyelin levels in Parkinson’s disease

Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson’s Disease

The role of sphingosine-1-phosphate in the development and progression of Parkinson's disease

Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson's disease

Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome

Lipidomic Profiling Reveals Shared and Distinct Pathological Signatures in Sporadic Parkinson's Disease and GBA Mutation Carriers: Implications for Disease Mechanisms

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies

Role of Lipids in the Pathogenesis of Parkinson's Disease

Elevated serum anti-<i> Saccharomyces</i><i> cerevisiae</i> antibody accompanied by gut mycobiota dysbiosis as a biomarker of diagnosis in patients with de novo Parkinson disease

The function of sphingolipids in different pathogenesis of Alzheimer's disease: A comprehensive review

The Role of Alpha Synuclein in Synucleinopathy: Impact on Lipid Regulation at Mitochondria ER Membranes

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson’s Disease

Bioactive lipids and their metabolism: New therapeutic opportunities for Parkinson's disease

Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis

Multi-Omic Analysis Reveals Lipid Dysregulation Associated with Mitochondrial Dysfunction in Parkinson's Disease Brain

Reducing the lipase LIPE in mutant α-synuclein mice improves Parkinson-like deficits and reveals sex differences in fatty acid metabolism

Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease

Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis

Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease

The Relationship among Amyloid-Β Deposition, Sphingomyelin Level, and the Expression and Function of P-glycoprotein in Alzheimer’s Disease Pathological Process

Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease